Werewolf Therapeutics, Inc. HOWL
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +55.47%
- 1 year
- +6.56%
5D -0.0192 (-1.90%)
- Market cap
- 47.90M
- Revenue (ttm)
- 3.39M
- EPS (ttm)
- -0.58
- Shares out
- 44.56M
- Forward P/E
- -0.86
- YTD return
- +55.47%
- 1-year return
- +6.56%
- 50-day average
- 2.11
- Volume
- 560.85K
- Avg volume
- 6.73M
- Open
- 1.01
- Previous close
- 1.03
- Day's range
- 0.95 – 1.01
- 52-week range
- 0.27 – 1.20
- Beta
- 0.41
- Price target
- 12.00 (+1117.4%)
Key statistics
- 200-day average
- 3.31
- Enterprise value
- -15.19M
- Price / sales
- 20.66
- Price / book
- 0.77
- Free cash flow
- -27.67M
- Total cash
- 122.83M
- Total debt
- 36.78M
- Return on equity
- -61.56%
- Short % of float
- 4.67%
Fundamental scorecard
8 of 25 checks passed on HOWL’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.41 | -0.38 | +0.03 | +7.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | -0.43 | -0.05 | -13.16% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | — | — | — |
| May 3, 2024 | Mar 1, 2024 | -0.35 | -0.39 | -0.04 | -11.43% |
| May 3, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.43 | -0.33 | +0.10 | +23.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- werewolftx.com
News
Your note
Sign in to keep a note on HOWL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13.79% | 6,144,881 | 9.65M | Sep 29, 2024 |
| MPM Asset Management, LLC | 9.61% | 4,284,172 | 6.73M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 7.63% | 3,398,747 | 5.34M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 5.36% | 2,388,011 | 3.75M | Sep 29, 2024 |
| Bank of America Corporation | 4.83% | 2,153,717 | 3.38M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.49% | 2,000,594 | 3.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.80% | 800,282 | 1.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.52% | 676,891 | 1.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 392,161 | 615.69K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.70% | 310,654 | 487.73K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.48% | 211,769 | 332.48K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 171,305 | 268.95K | Oct 30, 2024 |
